AIM: Current chemotherapy for esophageal cancer is conducted on the basis of empirical information from clinical trials, which fails to take into account the known heterogeneity of chemosensitivity between patients. This study was aimed to demonstrate the degree of heterogeneity of chemosensitivity in esophageal cancers. METHODS: A total of 42 esophageal cancer specimens were collected. The heterogeneity of chemosensitivity in esophageal cancer specimens was examined using an ex vivo ATP-tumor chemosensitivity assay (ATP-TCA). RESULTS: Thirty eight specimens produced evaluable results (90.5%). The most active single agent tested was nedaplatin, to which 28.9% of samples were sensitive. Combinations of chemotherapy agents exhibited much higher sensitivity: cisplatin + paclitaxel was sensitive in 16 of 38 (42.1%) of samples, while nedaplatin+paclitaxel was more effective, which was sensitive in 20 of 38 cases (52.6%). CONCLUSION: There was a marked heterogeneity of chemosensitivity in esophageal cancer. Chemosensitivity testing may provide a practical method for testing new regimens before clinical trials in esophageal cancer patients.
AIM: Current chemotherapy for esophageal cancer is conducted on the basis of empirical information from clinical trials, which fails to take into account the known heterogeneity of chemosensitivity between patients. This study was aimed to demonstrate the degree of heterogeneity of chemosensitivity in esophageal cancers. METHODS: A total of 42 esophageal cancer specimens were collected. The heterogeneity of chemosensitivity in esophageal cancer specimens was examined using an ex vivo ATP-tumor chemosensitivity assay (ATP-TCA). RESULTS: Thirty eight specimens produced evaluable results (90.5%). The most active single agent tested was nedaplatin, to which 28.9% of samples were sensitive. Combinations of chemotherapy agents exhibited much higher sensitivity: cisplatin + paclitaxel was sensitive in 16 of 38 (42.1%) of samples, while nedaplatin+paclitaxel was more effective, which was sensitive in 20 of 38 cases (52.6%). CONCLUSION: There was a marked heterogeneity of chemosensitivity in esophageal cancer. Chemosensitivity testing may provide a practical method for testing new regimens before clinical trials in esophageal cancerpatients.
Authors: G Konecny; C Crohns; M Pegram; M Felber; S Lude; C Kurbacher; I A Cree; H Hepp; M Untch Journal: Gynecol Oncol Date: 2000-05 Impact factor: 5.482
Authors: Stuart J Mercer; Shaw S Somers; Louise A Knight; Pauline A Whitehouse; Sanjay Sharma; Federica Di Nicolantonio; Sharon Glaysher; Simon Toh; Ian A Cree Journal: Anticancer Drugs Date: 2003-07 Impact factor: 2.248
Authors: Federica Di Nicolantonio; Louise A Knight; Silvana Di Palma; Sanjay Sharma; Pauline A Whitehouse; Stuart J Mercer; Peter A Charlton; David Norris; Ian A Cree Journal: Anticancer Drugs Date: 2004-10 Impact factor: 2.248
Authors: Pauline A Whitehouse; Louise A Knight; Federica Di Nicolantonio; Stuart J Mercer; Sanjay Sharma; Ian A Cree Journal: Anticancer Drugs Date: 2003-06 Impact factor: 2.248
Authors: Sanjay Sharma; Michael H Neale; Federica Di Nicolantonio; Louise A Knight; Pauline A Whitehouse; Stuart J Mercer; Bernard R Higgins; Alan Lamont; Richard Osborne; Andrew C Hindley; Christian M Kurbacher; Ian A Cree Journal: BMC Cancer Date: 2003-07-03 Impact factor: 4.430